RINVOQ® (upadacitinib) Dosing and Lab Monitoring Inform patients that retinal detachment has been reported in clinical trials with RINVOQ Advise patients to immediately inform their healthcare provider if they develop any sudden changes in vision while receiving RINVOQ Dosage Forms and Strengths: RINVOQ is available in 15 mg, 30 mg, and 45 mg extended-release tablets RINVOQ LQ is available
RINVOQ® (upadacitinib) Dosing for Ulcerative Colitis and Crohns Disease Inform patients that retinal detachment has been reported in clinical trials with RINVOQ Advise patients to immediately inform their healthcare provider if they develop any sudden changes in vision while receiving RINVOQ Dosage Forms and Strengths: RINVOQ is available in 15 mg, 30 mg, and 45 mg extended-release tablets RINVOQ LQ is available
RINVOQ® (upadacitinib) PRODUCT FACT SHEET DOSAGE AND ADMINISTRATION1 For RA PsA AS nr-axSpA: The recommended oral dose is 15 mg once daily For AD: For adults <65 years of age and pediatric patients 12 years of age and older weighing at least 40 kg: • Initiate treatment with 15 mg once daily • If an adequate response is not achieved, consider increasing the dosage to 30 mg once daily
RINVOQ® (upadacitinib) Dosing for Atopic Dermatitis Inform patients that retinal detachment has been reported in clinical trials with RINVOQ Advise patients to immediately inform their healthcare provider if they develop any sudden changes in vision while receiving RINVOQ Dosage Forms and Strengths: RINVOQ is available in 15 mg, 30 mg, and 45 mg extended-release tablets RINVOQ LQ is available
RINVOQ® (upadacitinib) Ulcerative Colitis Dosing Guide The recommended dose of RINVOQ for maintenance treatment is 15 mg once daily 1 A maintenance dose of 30 mg once daily may be considered for patients with refractory, severe, or extensive disease Discontinue RINVOQ if an adequate therapeutic response is not achieved with the 30 mg dose Use the lowest effective dosage needed to maintain response 1
RINVOQ® (upadacitinib) - Official Healthcare Professional Site Inform patients that retinal detachment has been reported in clinical trials with RINVOQ Advise patients to immediately inform their healthcare provider if they develop any sudden changes in vision while receiving RINVOQ Dosage Forms and Strengths: RINVOQ is available in 15 mg, 30 mg, and 45 mg extended-release tablets RINVOQ LQ is available
RINVOQ® (upadacitinib) for Ulcerative Colitis Inform patients that retinal detachment has been reported in clinical trials with RINVOQ Advise patients to immediately inform their healthcare provider if they develop any sudden changes in vision while receiving RINVOQ Dosage Forms and Strengths: RINVOQ is available in 15 mg, 30 mg, and 45 mg extended-release tablets RINVOQ LQ is available
RINVOQ® (upadacitinib) Dosing for RA, PsA, AS, nr-axSpA, and GCA Inform patients that retinal detachment has been reported in clinical trials with RINVOQ Advise patients to immediately inform their healthcare provider if they develop any sudden changes in vision while receiving RINVOQ Dosage Forms and Strengths: RINVOQ is available in 15 mg, 30 mg, and 45 mg extended-release tablets RINVOQ LQ is available
RINVOQ® (upadacitinib) for Rheumatoid Arthritis Advise patients to immediately inform their healthcare provider if they develop any sudden changes in vision while receiving RINVOQ Dosage Forms and Strengths: RINVOQ is available in 15 mg, 30 mg, and 45 mg extended-release tablets RINVOQ LQ is available in a 1 mg mL oral solution
RINVOQ® (upadacitinib) for Crohns Disease Inform patients that retinal detachment has been reported in clinical trials with RINVOQ Advise patients to immediately inform their healthcare provider if they develop any sudden changes in vision while receiving RINVOQ Dosage Forms and Strengths: RINVOQ is available in 15 mg, 30 mg, and 45 mg extended-release tablets RINVOQ LQ is available